J. O'Connor

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.

G. Jayson, C. Dive, A. Renehan, 2019, European journal of cancer.

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

D. Heitjan, M. Benson, C. Olsson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

M. Benson, C. Olsson, J. Newhouse, 1999, Seminars in oncology.

Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.

E. Small, D. Petrylak, E. Crawford, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically. ATM inhibitor AZD0156 potentiates IR and olaparib response.

B. Barlaam, E. Cadogan, G. Hughes, 2019 .

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

D. Scheinberg, R. Stone, M. Kalaycio, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining glycolytic inhibitors with chemotherapy: Phase I trial of 2-deoxyglucose and docetaxel in patients with solid tumors

J. Schlesselman, K. Papadopoulos, T. Lampidis, 2005 .